PARTNERING

STRATEGIC ALLIANCES

Partners

Amarin has licensed to Multicell Technologies Inc exclusive, worldwide rights of MCT-125 for the treatment of fatigue in patients suffering from multiple sclerosis.

Collaborations

Amarin has collaborations for its development programs with the following institutes:

• Huntington's and Parkinson's Study Groups, University of Rochester
• Trinity College Dublin, Ireland
• Max Planck Institute, Germany
• University of Bradford, UK
• University of Prince Edward Island, Canada
• Participating in EU funded multi-intuitional research programme.